Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial-Reference-Cited by-同舟云学术

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial

Published:2022 Issue:0 Volume:0 Page:0
ISSN:1008-682X
Container-title:Asian Journal of Andrology
language:en
Short-container-title:Asian J Androl

Author:

Ye Ding-Wei,Chung ByungHa,Huang Jian,Ye Zhang-Qun,He Da-Lin,Uemura Hirotsugu,Arai Gaku,Kim ChoungSoo,Zhang Yuan-Yuan,Koroki Yusoke,Jeong SuYeon,Mundle Suneel,Triantos Spyros,McCarthy Sharon,Chi KimN

Publisher

Medknow

Subject

Urology,General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis;Prostate International;2024-08

2. Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study;Prostate Cancer and Prostatic Diseases;2024-07-05

3. Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial;Frontiers in Oncology;2023-11-06

4. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium;Japanese Journal of Clinical Oncology;2023-10-14

5. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial;Asian Journal of Andrology;2023